These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 11641970)

  • 1. Disseminated M. avium complex infection in the Swiss HIV Cohort Study: declining incidence, improved prognosis and discontinuation of maintenance therapy.
    Rossi M; Flepp M; Telenti A; Schiffer V; Egloff N; Bucher H; Vernazza P; Bernasconi E; Weber R; Rickenbach M; Furrer H;
    Swiss Med Wkly; 2001 Aug; 131(31-32):471-7. PubMed ID: 11641970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study.
    Furrer H; Telenti A; Rossi M; Ledergerber B
    AIDS; 2000 Jul; 14(10):1409-12. PubMed ID: 10930156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.
    Currier JS; Williams PL; Koletar SL; Cohn SE; Murphy RL; Heald AE; Hafner R; Bassily EL; Lederman HM; Knirsch C; Benson CA; Valdez H; Aberg JA; McCutchan JA
    Ann Intern Med; 2000 Oct; 133(7):493-503. PubMed ID: 11015162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of disseminated Mycobacterium avium-complex infection in HIV patients receiving antiretroviral therapy with use of Mycobacterium avium-complex prophylaxis.
    Jung Y; Song KH; Choe PG; Park WB; Bang JH; Kim ES; Kim HB; Park SW; Kim NJ; Oh MD
    Int J STD AIDS; 2017 Dec; 28(14):1426-1432. PubMed ID: 28592210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection.
    Lazaro E; Coureau G; Guedj J; Blanco P; Pellegrin I; Commenges D; Dabis F; Moreau JF; Pellegrin JL; Thiébaut R;
    Antivir Ther; 2006; 11(3):343-50. PubMed ID: 16759051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis.
    Zeller V; Truffot C; Agher R; Bossi P; Tubiana R; Caumes E; Jouan M; Bricaire F; Katlama C
    Clin Infect Dis; 2002 Mar; 34(5):662-7. PubMed ID: 11810599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy.
    Kirk O; Reiss P; Uberti-Foppa C; Bickel M; Gerstoft J; Pradier C; Wit FW; Ledergerber B; Lundgren JD; Furrer H;
    Ann Intern Med; 2002 Aug; 137(4):239-50. PubMed ID: 12186514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disseminated Mycobacterium avium complex disease in the Swiss HIV Cohort Study: increasing incidence, unchanged prognosis.
    Low N; Pfluger D; Egger M
    AIDS; 1997 Jul; 11(9):1165-71. PubMed ID: 9233465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART?
    Yangco BG; Buchacz K; Baker R; Palella FJ; Armon C; Brooks JT;
    AIDS Patient Care STDS; 2014 Jun; 28(6):280-3. PubMed ID: 24833016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD.
    Kirk O; Gatell JM; Mocroft A; Pedersen C; Proenca R; Brettle RP; Barton SE; Sudre P; Phillips AN
    Am J Respir Crit Care Med; 2000 Sep; 162(3 Pt 1):865-72. PubMed ID: 10988097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycobacterium tuberculosis infection and disease are not associated with protection against subsequent disseminated M. avium complex disease.
    Sterling TR; Moore RD; Graham NM; Astemborski J; Vlahov D; Chaisson RE
    AIDS; 1998 Aug; 12(12):1451-7. PubMed ID: 9727565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy.
    Shafran SD; Mashinter LD; Phillips P; Lalonde RG; Gill MJ; Walmsley SL; Toma E; Conway B; Fong IW; Rachlis AR; Williams KE; Garber GE; Schlech WF; Smaill F; Pradier C
    Ann Intern Med; 2002 Nov; 137(9):734-7. PubMed ID: 12416943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS.
    El-Sadr WM; Burman WJ; Grant LB; Matts JP; Hafner R; Crane L; Zeh D; Gallagher B; Mannheimer SB; Martinez A; Gordin F
    N Engl J Med; 2000 Apr; 342(15):1085-92. PubMed ID: 10766581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuation of primary prophylaxis against Mycobacterium avium complex infection in HIV-infected persons receiving antiretroviral therapy: observations from a large national cohort in the United States, 1992-2002.
    Brooks JT; Song R; Hanson DL; Wolfe M; Swerdlow DL;
    Clin Infect Dis; 2005 Aug; 41(4):549-53. PubMed ID: 16028167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azithromycin prophylaxis for Mycobacterium avium complex during the era of highly active antiretroviral therapy: evaluation of a provincial program.
    Phillips P; Chan K; Hogg R; Bessuille E; Black W; Talbot J; O'Shaughnessy M; Montaner J
    Clin Infect Dis; 2002 Feb; 34(3):371-8. PubMed ID: 11774085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy.
    Karakousis PC; Moore RD; Chaisson RE
    Lancet Infect Dis; 2004 Sep; 4(9):557-65. PubMed ID: 15336223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Macrolide Prophylactic Therapy on AIDS-Defining Conditions and HIV-Associated Mortality.
    Pasayan MKU; S Mationg ML; Boettiger D; Lam W; Zhang F; Ku SW; Merati TP; Chaiwarith R; Cuong DD; Yunihastuti E; Kiertiburanakul S; Van Kinh N; Avihingsanon A; Sun LP; Kamarulzaman A; Kantipong P; Kumarasamy N; Pujari S; Heng Sim BL; Ng OT; Choi JY; Tanuma J; Ross J; A Ditangco R
    J Acquir Immune Defic Syndr; 2019 Apr; 80(4):436-443. PubMed ID: 30550488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disseminated mycobacterium avium-intracellulare complex (MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated?
    Lange CG; Woolley IJ; Brodt RH
    Drugs; 2004; 64(7):679-92. PubMed ID: 15025543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of disseminated Mycobacterium avium-complex infection on survival of HIV-infected patients.
    Brodt HR; Enzensberger R; Kamps BS; Keul HG; Helm EB
    Eur J Med Res; 1997 Mar; 2(3):106-10. PubMed ID: 9113499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment and prophylaxis of disseminated Mycobacterium avium complex in HIV-infected individuals.
    Faris MA; Raasch RH; Hopfer RL; Butts JD
    Ann Pharmacother; 1998 May; 32(5):564-73. PubMed ID: 9606478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.